New Drugs and Treatment Regimens

Author(s): Derek J. Sloan, Geraint R. Davies, Saye H. Khoo

Journal Name: Current Respiratory Medicine Reviews

Volume 9 , Issue 3 , 2013

Become EABM
Become Reviewer


The current treatment regimen against drug susceptible tuberculosis (DS-TB) was defined by the 1980s. Since then the emergence of the global HIV pandemic and the escalation of drug resistant (DR-) forms of TB have presented new challenges for therapeutic research. Priority goals include shortening DS-TB treatment, improving DR-TB treatment and making combined TB-HIV therapy easier. To help achieve these goals, a range of new drugs and treatment strategies are currently being evaluated. Phase IIb and III clinical trials are ongoing to assess combinations involving the high-dose rifamycins, the 8-methoxyquinolones, a diarylquinoline (bedaquiline) and the nitroimidazoles. Other compounds (e.g. novel oxazolidinones and ethylenediamines) are at earlier stages of clinical development. Overall, there are grounds for optimism that recent advances will contribute towards achievement of new treatment regimens in the foreseeable future. However, long-term investment, political commitment and scientific endeavour are crucial to ensure that progress is sustained and the benefits of recent advances reach those in the greatest need.

Keywords: Bedaquiline (TMC-207), Delamanid (OPC-67683), Gatifloxacin, Moxifluxacin, PA-824, Rifampicin, Rifapentine, sterilising activity.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [200 - 210]
Pages: 11
DOI: 10.2174/1573398X113099990017
Price: $65

Article Metrics

PDF: 8